Liposomes as ‘smart’ pharmaceutical nanocarriers
暂无分享,去创建一个
[1] T. Honda,et al. Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice , 2008, Clinical Cancer Research.
[2] U. Nielsen,et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.
[3] Joachim Kohn,et al. pH triggered release of protective poly(ethylene glycol)-b-polycation copolymers from liposomes. , 2006, Biomaterials.
[4] M. Dewhirst,et al. Hyperthermia mediated liposomal drug delivery , 2006, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[5] L. Huang,et al. pH-sensitive immunoliposomes as an efficient and target-specific carrier for antitumor drugs. , 1986, Cancer research.
[6] P. Okunieff,et al. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.
[7] He Zhang,et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. , 2009, International journal of pharmaceutics.
[8] Philip S Low,et al. Folate-mediated delivery of macromolecular anticancer therapeutic agents. , 2002, Advanced drug delivery reviews.
[9] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[10] C. Mamot,et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.
[11] Pallab Pradhan,et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.
[12] M. Shono,et al. Kinetic analysis of endocytosis and intracellular fate of liposomes in single macrophages. , 1995, Journal of biochemistry.
[13] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[14] J. Zia,et al. Poly(2-alkylacrylic acid) polymers deliver molecules to the cytosol by pH-sensitive disruption of endosomal vesicles. , 2003, The Biochemical journal.
[15] G. Hardee,et al. Folate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo. , 2003, Bioconjugate chemistry.
[16] Raimon Sabaté,et al. Preparation and characterization of extruded magnetoliposomes. , 2008, International journal of pharmaceutics.
[17] S. Futaki,et al. An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives , 2008, Analytical and bioanalytical chemistry.
[18] F. Szoka,et al. Mechanism of pH-triggered collapse of phosphatidylethanolamine liposomes stabilized by an ortho ester polyethyleneglycol lipid. , 2003, Biophysical journal.
[19] In-Young Kim,et al. Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes , 2008, Archives of pharmacal research.
[20] E. Chang,et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.
[21] D. Tzemach,et al. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. , 1999, Anti-cancer drugs.
[22] U. Nielsen,et al. Tumor targeting using anti-her2 immunoliposomes. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[23] J. Leroux,et al. In vitro characterization of a novel polymeric-based pH-sensitive liposome system. , 2000, Biochimica et biophysica acta.
[24] F. Khuri,et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. , 2001, Lung cancer.
[25] V. Torchilin. Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.
[26] H. Maeda,et al. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[27] J. Schellens,et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.
[28] D. Fischer,et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[29] Vladimir P Torchilin,et al. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.
[30] D. Thompson,et al. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[31] S. Soenen,et al. Surface functionalization of magnetoliposomes in view of improving iron oxide-based magnetic resonance imaging contrast agents: anchoring of gadolinium ions to a lipophilic chelate. , 2007, Analytical biochemistry.
[32] R. Jain,et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[33] Robert Langer,et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers , 2008, Proceedings of the National Academy of Sciences.
[34] K. Kono,et al. Effect of poly(ethylene glycol) grafts on temperature-sensitivity of thermosensitive polymer-modified liposomes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[35] R. Bankert,et al. THE NEXT GENERATION OF LIPOSOME DELIVERY SYSTEMS: RECENT EXPERIENCE WITH TUMOR-TARGETED, STERICALLY-STABILIZED IMMUNOLIPOSOMES AND ACTIVE-LOADING GRADIENTS , 2002, Journal of liposome research.
[36] Bhawna Gupta,et al. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice , 2007, Cancer Immunology, Immunotherapy.
[37] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[38] Qiang Zhang,et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. , 2005, Journal of pharmaceutical sciences.
[39] H. Karanth,et al. pH‐Sensitive liposomes‐principle and application in cancer therapy , 2007, The Journal of pharmacy and pharmacology.
[40] V. Torchilin. Liposomes as targetable drug carriers. , 1985, Critical reviews in therapeutic drug carrier systems.
[41] P. Cullis,et al. Poly(ethylene glycol)--lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine. , 1996, Biochemistry.
[42] V. Cardoso,et al. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor-bearing mice. , 2007, Life sciences.
[43] J. Hughes,et al. Use of dithiodiglycolic acid as a tether for cationic lipids decreases the cytotoxicity and increases transgene expression of plasmid DNA in vitro. , 1999, Bioconjugate chemistry.
[44] Theresa M Allen,et al. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.
[45] G. Storm,et al. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. , 1993, Biochimica et biophysica acta.
[46] Kyung-Dall Lee,et al. Differential cytosolic delivery and presentation of antigen by listeriolysin O-liposomes to macrophages and dendritic cells. , 2005, Molecular pharmaceutics.
[47] P. Cullis,et al. Drug Delivery Systems: Entering the Mainstream , 2004, Science.
[48] K. Fujimoto,et al. A reduction-triggered delivery by a liposomal carrier possessing membrane-permeable ligands and a detachable coating. , 2006, Colloids and surfaces. B, Biointerfaces.
[49] J. Haveman,et al. The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[50] A. Gabizon,et al. Liposome circulation time and tumor targeting: implications for cancer chemotherapy , 1995 .
[51] James B. Mitchell,et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. , 2002, Cancer research.
[52] T M Allen,et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.
[53] Olivier Meyer,et al. Copolymers of N‐isopropylacrylamide can trigger pH sensitivity to stable liposomes , 1998, FEBS letters.
[54] I. Ojima,et al. Recent advances in tumor-targeting anticancer drug conjugates. , 2005, Bioorganic & medicinal chemistry.
[55] A. Gabizon,et al. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[56] M. Lafleur,et al. On the characterization of pH-sensitive liposome/polymer complexes. , 2003, Biomacromolecules.
[57] R. Scheule,et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. , 1997, Human gene therapy.
[58] K. Kono,et al. Temperature sensitization of liposomes using copolymers of N-isopropylacrylamide. , 1999, Bioconjugate chemistry.
[59] P. Low,et al. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[60] M. Zignani,et al. Current status of pH-sensitive liposomes in drug delivery. , 2000, Progress in lipid research.
[61] I. Rubinstein,et al. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[62] S. Yamada,et al. Feasibility of magnetic liposomes as a targeting device for drugs. , 1986, Chemical & pharmaceutical bulletin.
[63] Y. Oh,et al. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[64] Vladimir P Torchilin,et al. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. , 2008, Biopolymers.
[65] Vladimir P Torchilin,et al. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[66] Joel A Swanson,et al. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.
[67] Francesco M Veronese,et al. PEGylation, successful approach to drug delivery. , 2005, Drug discovery today.
[68] Samuel Zalipsky,et al. Liposomes with detachable polymer coating: destabilization and fusion of dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface‐grafted poly(ethylene glycol) , 1996, FEBS letters.
[69] You Han Bae,et al. Drug targeting and tumor heterogeneity. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[70] I Horikoshi,et al. Magnetic targeting of thermosensitive magnetoliposomes to mouse livers in an in situ on-line perfusion system. , 1995, Life sciences.
[71] N. Phillips,et al. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. , 1997, Biochimica et biophysica acta.
[72] V. Torchilin,et al. Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. , 2007, Bioconjugate chemistry.
[73] S. Simões,et al. Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides , 1998, Gene Therapy.
[74] W. Hennink,et al. Temperature-sensitive poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-coated liposomes for triggered contents release. , 2007, Bioconjugate chemistry.
[75] Paras N Prasad,et al. Diacyllipid micelle-based nanocarrier for magnetically guided delivery of drugs in photodynamic therapy. , 2006, Molecular pharmaceutics.
[76] Ingrid Hilger,et al. Thermal Ablation of Tumors Using Magnetic Nanoparticles: An In Vivo Feasibility Study , 2002, Investigative radiology.
[77] F. Szoka,et al. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. , 1996, Biochemistry.
[78] J. Legendre,et al. Delivery of Plasmid DNA into Mammalian Cell Lines Using pH-Sensitive Liposomes: Comparison with Cationic Liposomes , 1992, Pharmaceutical Research.
[79] H. Arai,et al. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. , 1990, The Journal of biological chemistry.
[80] A. Gabizon,et al. Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times. , 1991, Biochimica et biophysica acta.
[81] G Gregoriadis,et al. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.
[82] P. Low,et al. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[83] H. Yanagie,et al. Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.
[84] J. Behr,et al. Transfection and physical properties of various saccharide, poly(ethylene glycol), and antibody‐derivatized polyethylenimines (PEI) , 1999, The journal of gene medicine.
[85] F. Chang,et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[86] Hui Zhao,et al. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer , 2009, Journal of drug targeting.
[87] Yukikazu Natori,et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. , 2009, Molecular pharmaceutics.
[88] Qiang Zhang,et al. Enhanced Intracellular Uptake of Sterically Stabilized Liposomal Doxorubicin in Vitro Resulting in Improved Antitumor Activity in Vivo , 2005, Pharmaceutical Research.
[89] F. Szoka,et al. Low‐pH‐sensitive poly(ethylene glycol) (PEG)‐stabilized plasmid nanolipoparticles: effects of PEG chain length, lipid composition and assembly conditions on gene delivery , 2005, The journal of gene medicine.
[90] John W. Park,et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. , 1997, Biochemistry.
[91] A. Hoffman,et al. pH-sensitive polymers that enhance intracellular drug delivery in vivo. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[92] E. K. Park,et al. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. , 2004, Biomaterials.
[93] K. Kono,et al. Targetability and intracellular delivery of anti-BCG antibody-modified, pH-sensitive fusogenic immunoliposomes to tumor cells. , 2002, International journal of pharmaceutics.
[94] K. Kono,et al. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. , 1997, Biochimica et biophysica acta.
[95] Wenjin Guo,et al. Efficient intracellular drug and gene delivery using folate receptor-targeted pH-sensitive liposomes composed of cationic/anionic lipid combinations. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[96] K Mechtler,et al. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. , 1994, The Journal of biological chemistry.
[97] M. Yatvin,et al. pH-sensitive liposomes: possible clinical implications. , 1980, Science.
[98] D. Scherman,et al. Design, synthesis, and evaluation of gadolinium cationic lipids as tools for biodistribution studies of gene delivery complexes. , 2003, Bioconjugate chemistry.
[99] B Poole,et al. Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[100] K. Maruyama,et al. Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. , 1991, Chemical & pharmaceutical bulletin.
[101] M. Basu,et al. Macrophage specific drug delivery in experimental leishmaniasis. , 2004, Current molecular medicine.
[102] T. Ishida,et al. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. , 2001, Biochimica et biophysica acta.
[103] C. M. Gupta,et al. Tuftsin-bearing liposomes in treatment of macrophage-based infections. , 2000, Advanced drug delivery reviews.
[104] Y. Kawashima,et al. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[105] T. Allen,et al. Ligand-targeted liposomal anticancer drugs. , 2003, Progress in lipid research.
[106] I. Hafez,et al. Cholesteryl hemisuccinate exhibits pH sensitive polymorphic phase behavior. , 2000, Biochimica et biophysica acta.
[107] Yu Zhou,et al. Impact of single-chain Fv antibody fragment affinity on nanoparticle targeting of epidermal growth factor receptor-expressing tumor cells. , 2007, Journal of molecular biology.
[108] W. Hennink,et al. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. , 2003, Bioconjugate chemistry.
[109] M. Dewhirst,et al. Drug targeting using thermally responsive polymers and local hyperthermia. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[110] A. Gabizon. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.
[111] T. Allen. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte system , 1994 .
[112] T. Suhara,et al. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. , 2004, International journal of pharmaceutics.
[113] Yechezkel Barenholz,et al. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs , 1993, Pharmaceutical Research.
[114] V. Torchilin,et al. Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo , 1991, FEBS letters.
[115] P. Couvreur,et al. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. , 2004, Advanced drug delivery reviews.
[116] S. Simões,et al. Sterically Stabilized pH-sensitive Liposomes , 1997, The Journal of Biological Chemistry.
[117] K. Kono,et al. Preparation of pH-sensitive poly(glycidol) derivatives with varying hydrophobicities: their ability to sensitize stable liposomes to pH. , 2008, Bioconjugate chemistry.
[118] P. Low,et al. Diplasmenylcholine−Folate Liposomes: An Efficient Vehicle for Intracellular Drug Delivery† , 1998 .
[119] P. Low,et al. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. , 1994, The Journal of biological chemistry.
[120] T. Allen,et al. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.
[121] R. Herrmann,et al. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells , 2006, Journal of drug targeting.
[122] A M Tsatsakis,et al. Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. , 2001, Biomaterials.
[123] V. Torchilin,et al. "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. , 2006, Bioconjugate chemistry.
[124] K. Kairemo,et al. Targeted liposomal drug delivery in cancer. , 2004, Current pharmaceutical design.
[125] T. Allen,et al. Pharmaco attributes of dioleoylphosphatidylethanolamine/cholesterylhemisuccinate liposomes containing different types of cleavable lipopolymers. , 2004, Pharmacological research.
[126] Wenjin Guo,et al. Characterization of a novel diolein-based LPDII vector for gene delivery. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[127] Halina D. Inerowicz,et al. Acid-Triggered Release from Sterically Stabilized Fusogenic Liposomes via a Hydrolytic DePEGylation Strategy† , 2003 .
[128] C. Ehrhardt,et al. In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[129] C. Shapiro,et al. Cardiac safety of liposomal anthracyclines. , 2004, Seminars in oncology.
[130] P. Low,et al. Optimization of folate-conjugated liposomal vectors for folate receptor-mediated gene therapy. , 1999, Journal of pharmaceutical sciences.
[131] H. Honda,et al. 4‐S‐Cysteaminylphenol‐loaded magnetite cationic liposomes for combination therapy of hyperthermia with chemotherapy against malignant melanoma , 2007, Cancer science.
[132] G Blume,et al. Molecular mechanism of the lipid vesicle longevity in vivo. , 1993, Biochimica et biophysica acta.
[133] S. Otto,et al. Reversible covalent chemistry in drug delivery. , 2005, Current drug discovery technologies.
[134] I. Saiki,et al. Microdialysis assessment of 5-fluorouracil release from thermosensitive magnetoliposomes induced by an electromagnetic field in tumor-bearing mice. , 1998, Journal of drug targeting.
[135] Ajay Kumar Gupta,et al. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.
[136] H. Shmeeda,et al. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors , 2006, Molecular Cancer Therapeutics.
[137] Ajay Kumar Gupta,et al. Recent advances on surface engineering of magnetic iron oxide nanoparticles and their biomedical applications. , 2007, Nanomedicine.
[138] Sanjay K. Jain,et al. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells , 2007, Journal of drug targeting.
[139] R K Jain,et al. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[140] T. Allen,et al. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. , 1995, Biochimica et biophysica acta.
[141] Samuel Zalipsky,et al. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[142] J. Kamps,et al. Uptake of Long-Circulating Immunoliposomes, Directed Against Colon Adenocarcinoma Cells, by Liver Metastases of Colon Cancer , 2000, Journal of drug targeting.
[143] Q. Ping,et al. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. , 2009, International journal of pharmaceutics.
[144] L. Gerweck,et al. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. , 1996, Cancer research.
[145] V. Torchilin,et al. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. , 2009, Molecular pharmaceutics.
[146] J. Zhang,et al. Lyophilized Paclitaxel Magnetoliposomes as a Potential Drug Delivery System for Breast Carcinoma via Parenteral Administration: In Vitro and in Vivo Studies , 2005, Pharmaceutical Research.
[147] L. J. Lee,et al. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery. , 2009, Journal of nanoscience and nanotechnology.
[148] D. Tzemach,et al. Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. , 1999, Bioconjugate chemistry.
[149] P. Cullis,et al. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. , 1991, Biochimica et biophysica acta.
[150] F. Dosio,et al. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.
[151] T. Yang,et al. Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells , 2007, Pharmaceutical Research.
[152] Rakesh K. Jain,et al. Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.
[153] F. Szoka,et al. Steric stabilization of fusogenic liposomes by a low-pH sensitive PEG--diortho ester--lipid conjugate. , 2001, Bioconjugate chemistry.
[154] Werner Tjarks,et al. A novel pH-sensitive liposome formulation containing oleyl alcohol. , 2002, Biochimica et biophysica acta.
[155] Sérgio Simões,et al. On the formulation of pH-sensitive liposomes with long circulation times. , 2004, Advanced drug delivery reviews.
[156] Theresa M. Allen,et al. Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.
[157] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[158] Robert J. Lee,et al. Targeted drug delivery via folate receptors , 2008, Expert opinion on drug delivery.
[159] V. Torchilin,et al. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[160] G. Gregoriadis,et al. Is half‐life of circulating liposomes determined by changes in their permeability? , 1982, FEBS letters.
[161] Jong-Mok Kim,et al. Cytoplasmic delivery of liposomal contents mediated by an acid-labile cholesterol-vinyl ether-PEG conjugate. , 2009, Bioconjugate chemistry.
[162] Vladimir Torchilin,et al. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[163] Y. Quinn,et al. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.
[164] V. Torchilin,et al. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.
[165] G. Scherphof,et al. Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. , 1981, Biochimica et biophysica acta.
[166] M. Dewhirst,et al. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.
[167] D. Papahadjopoulos,et al. pH‐sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules , 1985, FEBS letters.
[168] T. Ishida,et al. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. , 2006, International journal of pharmaceutics.
[169] D. Peer,et al. Loading mitomycin C inside long circulating hyaluronan targeted nano‐liposomes increases its antitumor activity in three mice tumor models , 2004, International journal of cancer.
[170] F. Szoka,et al. Chemical approaches to triggerable lipid vesicles for drug and gene delivery. , 2003, Accounts of chemical research.
[171] K. Kono,et al. Thermosensitive polymer-modified liposomes. , 2001, Advanced drug delivery reviews.
[172] Y. Yarden,et al. Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies. , 1996, British Journal of Cancer.
[173] P. Steerenberg,et al. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. , 1988, Biochimica et biophysica acta.
[174] T. Andresen,et al. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.
[175] Vladimir P Torchilin,et al. Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes , 2007, Journal of drug targeting.
[176] M. Hashida,et al. Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[177] P. Rose,et al. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. , 2005, The oncologist.
[178] Florence Gazeau,et al. Magnetic targeting of magnetoliposomes to solid tumors with MR imaging monitoring in mice: feasibility. , 2006, Radiology.
[179] K. Ulbrich,et al. POLY(HPMA)-COATED LIPOSOMES DEMONSTRATE PROLONGED CIRCULATION IN MICE , 2001, Journal of liposome research.
[180] R. Kontermann,et al. Immunoliposomes for cancer therapy. , 2006, Current opinion in molecular therapeutics.
[181] David H. Thompson,et al. Cytosolic drug delivery using pH- and light-sensitive liposomes. , 1999, Advanced drug delivery reviews.
[182] James B. Mitchell,et al. In vivo electron paramagnetic resonance imaging of tumor heterogeneity and oxygenation in a murine model. , 1998, Cancer research.
[183] K. Kono,et al. Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) derivative with carboxyl groups. , 1994, Biochimica et biophysica acta.
[184] V. Torchilin,et al. Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[185] Udo Greiser,et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.
[186] R. Bellamkonda,et al. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors. , 2009, Biomaterials.
[187] W. Shen,et al. Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. , 2003, Advanced drug delivery reviews.
[188] K. Mann,et al. Improved drug delivery to cancer cells: a method using magnetoliposomes that target epidermal growth factor receptors. , 2005, Medical hypotheses.
[189] R. Vile,et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[190] H. Maeda. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.
[191] Lin Zhu,et al. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. , 2009, International journal of pharmaceutics.
[192] H. Shmeeda,et al. Pros and Cons of the Liposome Platform in Cancer Drug Targeting , 2006, Journal of liposome research.
[193] P. Stauffer,et al. Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. , 1994, Cancer research.
[194] R. Mahato. Water insoluble and soluble lipids for gene delivery. , 2005, Advanced drug delivery reviews.
[195] H. Shmeeda,et al. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[196] E. A. Leite,et al. Acute toxicity of long-circulating and pH-sensitive liposomes containing cisplatin in mice after intraperitoneal administration. , 2009, Life sciences.
[197] L. Huang,et al. Highly efficient DNA delivery mediated by pH-sensitive immunoliposomes. , 1989, Biochemistry.
[198] K. Funato,et al. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. , 1992, Biochimica et biophysica acta.
[199] L. Huang,et al. Amphipathic poly(ethylene glycol) 5000-stabilized dioleoylphosphatidylethanolamine liposomes accumulate in spleen. , 1992, Biochimica et biophysica acta.
[200] M. Bally,et al. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. , 1994, Cancer research.
[201] V. Torchilin,et al. Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody , 2009, Clinical Cancer Research.
[202] K. Kono,et al. Thermosensitive polymer-modified liposomes that release contents around physiological temperature. , 1999, Biochimica et biophysica acta.
[203] Francis C. Szoka,et al. pH-Sensitive Liposomes , 1994 .
[204] R. Schiffelers,et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[205] T. Allen,et al. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.
[206] L. Pilarski,et al. Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells , 1999 .
[207] Hiroyuki Honda,et al. Medical application of functionalized magnetic nanoparticles. , 2005, Journal of bioscience and bioengineering.
[208] R. B. Campbell,et al. The drug loading, cytotoxicty and tumor vascular targeting characteristics of magnetite in magnetic drug targeting. , 2007, Biomaterials.
[209] R Blumenthal,et al. Design of liposomes for enhanced local release of drugs by hyperthermia. , 1978, Science.
[210] M. Woodle. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. , 1993, Chemistry and physics of lipids.
[211] D. Thompson,et al. Triggerable plasmalogen liposomes: improvement of system efficiency. , 1996, Biochimica et biophysica acta.
[212] E. Moase,et al. Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer , 2008, Journal of drug targeting.
[213] Andrew D. Miller,et al. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. , 2008, Bioconjugate chemistry.
[214] E. Choi,et al. Enhancement of radiotherapeutic effectiveness by temperature-sensitive liposomal 1-methylxanthine. , 2009, International journal of pharmaceutics.
[215] C. Alving,et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[216] Ho-Suk Choi,et al. Doxorubicin-encapsulated thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-acrylamide): drug release behavior and stability in the presence of serum. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[217] M. Yessine,et al. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. , 2004, Advanced drug delivery reviews.